<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36982140</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5065</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24065065</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a clinically highly heterogeneous disease with a survival rate ranging from months to decades. Evidence suggests that a systemic deregulation of immune response may play a role and affect disease progression. Here, we measured 62 different immune/metabolic mediators in plasma of sporadic ALS (sALS) patients. We show that, at the protein level, the majority of immune mediators including a metabolic sensor, leptin, were significantly decreased in the plasma of sALS patients and in two animal models of the disease. Next, we found that a subset of patients with rapidly progressing ALS develop a distinct plasma assess immune-metabolic molecular signature characterized by a differential increase in soluble tumor necrosis factor receptor II (sTNF-RII) and chemokine (C-C motif) ligand 16 (CCL16) and further decrease in the levels of leptin, mostly dysregulated in male patients. Consistent with in vivo findings, exposure of human adipocytes to sALS plasma and/or sTNF-RII alone, induced a significant deregulation in leptin production/homeostasis and was associated with a robust increase in AMP-activated protein kinase (AMPK) phosphorylation. Conversely, treatment with an AMPK inhibitor restored leptin production in human adipocytes. Together, this study provides evidence of a distinct plasma immune profile in sALS which affects adipocyte function and leptin signaling. Furthermore, our results suggest that targeting the sTNF-RII/AMPK/leptin pathway in adipocytes may help restore assess immune-metabolic homeostasis in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Picher-Martel</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5620-6938</Identifier><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Qu&#xe9;bec, Department of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutej</LastName><ForeName>Hejer</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe9;zina</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0008-0295-3418</Identifier><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneb</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupr&#xe9;</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7270-6115</Identifier><AffiliationInfo><Affiliation>CHU de Qu&#xe9;bec, Department of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriz</LastName><ForeName>Jasna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1811-7456</Identifier><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Department of Psychiatry and Neuroscience, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, QC G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020/21</GrantID><Agency>ALS Society of Canada</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020738">Leptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.31</RegistryNumber><NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020738" MajorTopicYN="Y">Leptin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMPK</Keyword><Keyword MajorTopicYN="N">adipocytes</Keyword><Keyword MajorTopicYN="N">fast progressors</Keyword><Keyword MajorTopicYN="N">leptin</Keyword><Keyword MajorTopicYN="N">plasma</Keyword><Keyword MajorTopicYN="N">sALS</Keyword><Keyword MajorTopicYN="N">sTNF-RII</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36982140</ArticleId><ArticleId IdType="pmc">PMC10049559</ArticleId><ArticleId IdType="doi">10.3390/ijms24065065</ArticleId><ArticleId IdType="pii">ijms24065065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A., Hardiman O., Kiernan M.C., Chi&#xf2; A., Rix-Brooks B., van den Berg L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C., Glass J.D. Modeling the course of amyotrophic lateral sclerosis. Nat. Biotechnol. 2015;33:45&#x2013;47. doi: 10.1038/nbt.3118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3118</ArticleId><ArticleId IdType="pubmed">25574636</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Valdmanis P.N., Gould P.V., Julien J.-P., Dupr&#xe9; N. From animal models to human disease: A genetic approach for personalized medicine in ALS. Acta Neuropathol. Commun. 2016;4:1&#x2013;29. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E., Messina P., Logroscino G., Beghi E., the SLALOM Group Long-term survival in amyotrophic lateral sclerosis: A population-based study. Ann. Neurol. 2014;75:287&#x2013;297. doi: 10.1002/ana.24096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24096</ArticleId><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G. Classifying change and heterogeneity in amyotrophic lateral sclerosis. Lancet Neurol. 2016;15:1111&#x2013;1112. doi: 10.1016/S1474-4422(16)30206-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30206-X</ArticleId><ArticleId IdType="pubmed">27647633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M., Conte A., Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin. Genet. 2013;83:408&#x2013;416. doi: 10.1111/cge.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12117</ArticleId><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S., Beghi E., Palagano G., Fraddosio A., Guerra V., Samarelli V., Lepore V., Simone I.L., Lamberti P., Serlenga L., et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: A population based study. J. Neurol. Neurosurg. Psychiatry. 2008;79:33&#x2013;37. doi: 10.1136/jnnp.2007.118018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.118018</ArticleId><ArticleId IdType="pubmed">17550991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K., Mauss U., Krampfl K., Petri S., Dengler R., Mohammadi B. ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J. Neurol. Sci. 2008;275:69&#x2013;73. doi: 10.1016/j.jns.2008.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., Van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., Berg L.H.V.D., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis E.J., Mendiondo M.S., Matthews D.E., Mitsumoto H., Tandan R., Simmons Z., Bromberg M.B., Kryscio R.J. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 2014;99:792&#x2013;803. doi: 10.3945/ajcn.113.069997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.113.069997</ArticleId><ArticleId IdType="pmc">PMC3953880</ArticleId><ArticleId IdType="pubmed">24522445</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Martos C.M., Atkinson R.A.K., Chuah M.I., King A.E., Vickers J.C. Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2017;3:92&#x2013;106. doi: 10.1016/j.trci.2016.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.11.002</ArticleId><ArticleId IdType="pmc">PMC5651376</ArticleId><ArticleId IdType="pubmed">29067321</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Martos C.M., Gonz&#xe1;lez P., Rodriguez F.J. Acute leptin treatment enhances functional recovery after spinal cord injury. PLoS ONE. 2012;7:e35594. doi: 10.1371/journal.pone.0035594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035594</ArticleId><ArticleId IdType="pmc">PMC3334982</ArticleId><ArticleId IdType="pubmed">22536415</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr S.A., Banks W.A., Morley J.E. Effects of leptin on memory processing. Peptides. 2006;27:1420&#x2013;1425. doi: 10.1016/j.peptides.2005.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2005.10.006</ArticleId><ArticleId IdType="pubmed">16293343</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Alvarez J., Goberna R., S&#xe1;nchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell. Immunol. 1999;194:6&#x2013;11. doi: 10.1006/cimm.1999.1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cimm.1999.1490</ArticleId><ArticleId IdType="pubmed">10357875</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C., Dreyer M.G., Pellegrinelli N., Chicheportiche R., Meier C.A. Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J. Clin. Endocrinol. Metab. 2001;86:783&#x2013;791. doi: 10.1210/jc.86.2.783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.86.2.783</ArticleId><ArticleId IdType="pubmed">11158047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G., Peter R.S., Rosenbohm A., Koenig W., Dupuis L., Rothenbacher D., Ludolph A.C. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis&#x2014;Results from a population-based ALS registry in Germany. Sci. Rep. 2017;7:4374. doi: 10.1038/s41598-017-04706-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Steyn F.J., Huang L., Mantovani S., Pfluger C.M.M., Woodruff T.M., O&#x2019;Sullivan J., Henderson R., McCombe P. Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;357:22&#x2013;27. doi: 10.1016/j.jns.2015.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Donato A., Contreras A., Frago L.M., Chowen J.A., Fernandez-Martos C.M. Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS) Int. J. Mol. Sci. 2021;22:10305. doi: 10.3390/ijms221910305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910305</ArticleId><ArticleId IdType="pmc">PMC8508891</ArticleId><ArticleId IdType="pubmed">34638645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Donato A., Contreras A., Fernandez P., Fernandez-Martos C.M. The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS) Brain Behav. 2022;12:e2465. doi: 10.1002/brb3.2465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2465</ArticleId><ArticleId IdType="pmc">PMC8785645</ArticleId><ArticleId IdType="pubmed">34935299</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L.-C., Markovinovic A., Jakovac H., De Marchi F., Bilic E., Mazzini L., Kriz J., Munitic I. Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Renaud L., Bareil C., Julien J.-P. Neuronal Expression of UBQLN2P497H Exacerbates TDP-43 Pathology in TDP-43G348C Mice through Interaction with Ubiquitin. Mol. Neurobiol. 2019;56:4680&#x2013;4696. doi: 10.1007/s12035-018-1411-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1411-3</ArticleId><ArticleId IdType="pmc">PMC6647471</ArticleId><ArticleId IdType="pubmed">30377984</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoki K., Kim J., Guan K.-L. AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets. Annu. Rev. Pharmacol. Toxicol. 2012;52:381&#x2013;400. doi: 10.1146/annurev-pharmtox-010611-134537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010611-134537</ArticleId><ArticleId IdType="pubmed">22017684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.J., Wang Y., Ricci M.R., Sullivan S., Russell C.D., Fried S.K. Acute and chronic regulation of leptin synthesis, storage, and secretion by insulin and dexamethasone in human adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2007;292:E858&#x2013;E864. doi: 10.1152/ajpendo.00439.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00439.2006</ArticleId><ArticleId IdType="pubmed">17122089</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Oliveira G.H., Silva T.M., Lima W.G., Valadares H.M.S., Chaves V.E. Insulin as a hormone regulator of the synthesis and release of leptin by white adipose tissue. Peptides. 2018;106:49&#x2013;58. doi: 10.1016/j.peptides.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2018.06.007</ArticleId><ArticleId IdType="pubmed">29953915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell R.M., Freeman W.M., Randazzo W.T., Stephens H.E., Beard J.L., Simmons Z., Connor J.R. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009;72:14&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18987350</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Yang X., Gao L., Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7:e00637. doi: 10.1002/brb3.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Lindberg R.L.P., Regeniter A., Mehling M., Steck A.J., Kappos L., Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009;16:771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P., Carlesi C., Giungato P., Puxeddu I., Borroni B., Boss&#xf9; P., Migliorini P., Siciliano G., Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflamm. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Gao L., Zang D. Elevated levels of IFN-&#x3b3; in CSF and serum of patients with amyotrophic lateral sclerosis. PLoS ONE. 2015;10:e0136937. doi: 10.1371/journal.pone.0136937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136937</ArticleId><ArticleId IdType="pmc">PMC4557946</ArticleId><ArticleId IdType="pubmed">26332465</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu G.N., Kumar A., Chandra R., Puri S.K., Kalita J., Misra U.K. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem. Res. 2008;33:1145&#x2013;1149. doi: 10.1007/s11064-007-9564-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9564-x</ArticleId><ArticleId IdType="pubmed">18246426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Zecca C., Piccininni M., Benmahamed S., Dell&#x2019;Abate M.T., Barulli M.R., Capozzo R., Battista P., Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front. Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Allen K., Oei F., Leoni E., Kuhle J., Tree T., Fratta P., Sharma N., Sidle K., Howard R., et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Polverino A., Rucco R., Stillitano I., Bonavita S., Grimaldi M., Minino R., Pesoli M., Trojsi F., D&#x2019;Ursi A.M., Sorrentino G., et al. In Amyotrophic Lateral Sclerosis Blood Cytokines Are Altered, but Do Not Correlate with Changes in Brain Topology. Brain Connect. 2020;10:411&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">32731760</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., G&#xfc;nther R., Akg&#xfc;n K., Hermann A., Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci. Rep. 2020;10:5941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A., Pinto S., Gromicho M., Pereira M., Swash M., de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;398:50&#x2013;53. doi: 10.1016/j.jns.2019.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado L.d.G.R., Rocha N.P., de Souza L.C., Bicalho I.C.S., Gomez R.S., Vidigal-Lopes M., Braz N.F.T., Vieira &#xc9;.L.M., Teixeira A.L. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2018;394:69&#x2013;74. doi: 10.1016/j.jns.2018.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId><ArticleId IdType="pubmed">30219498</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P., Moreno J., Dom&#xed;nguez R., Aso E., Povedano M., Ferrer I. Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:546. doi: 10.3389/fneur.2017.00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00546</ArticleId><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Hooten K.G., Sieglaff D.H., Zhang A., Kalyana-Sundaram S., Traini C.M., Halsey W.S., Hughes A.M., Sathe G.M., et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74:677&#x2013;685. doi: 10.1001/jamaneurol.2017.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad M.F., Damani S., Gingerich R.L., Riad-Gabriel M.G., Khan A., Boyadjian R., Jinagouda S.D., El-Tawil K., Rude R.K., Kamdar V. Sexual dimorphism in plasma leptin concentration. J. Clin. Endocrinol. Metab. 1997;82:579&#x2013;584. doi: 10.1210/jc.82.2.579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.82.2.579</ArticleId><ArticleId IdType="pubmed">9024258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitery R.J., Ortega G., Salazar C.B.C. Leptin sexual dimorphism, insulin resistance, and body composition in normal weight prepubescent. Rev. Chil. Pediatr. 2020;91:924&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">33861829</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Mahaney M.C., Almasy L., MacCluer J.W., Blangero J., Jaquish C.E., Comuzzie A.G. Leptin&#x2019;s sexual dimorphism results from genotype by sex interactions mediated by testosterone. Obes. Res. 2002;10:14&#x2013;21. doi: 10.1038/oby.2002.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oby.2002.3</ArticleId><ArticleId IdType="pubmed">11786597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Wang S., Signore A.P., Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke. 2007;38:2329&#x2013;2336. doi: 10.1161/STROKEAHA.107.482786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.107.482786</ArticleId><ArticleId IdType="pubmed">17600230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fewlass D.C., Noboa K., Pi-Sunyer F.X., Johnston J.M., Yan S.D., Tezapsidis N. Obesity-related leptin regulates Alzheimer&#x2019;s Abeta. FASEB J. 2004;18:1870&#x2013;1878. doi: 10.1096/fj.04-2572com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.04-2572com</ArticleId><ArticleId IdType="pubmed">15576490</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco S.J., Sarkar S., Casadesus G., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci. Lett. 2009;455:191&#x2013;194. doi: 10.1016/j.neulet.2009.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.03.066</ArticleId><ArticleId IdType="pmc">PMC2681253</ArticleId><ArticleId IdType="pubmed">19429119</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco S.J., Sarkar S., Johnston J.M., Tezapsidis N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Commun. 2009;380:98&#x2013;104. doi: 10.1016/j.bbrc.2009.01.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.01.041</ArticleId><ArticleId IdType="pmc">PMC2657956</ArticleId><ArticleId IdType="pubmed">19166821</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., Yin X.-M., Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem. 2007;282:34479&#x2013;34491. doi: 10.1074/jbc.M705426200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705426200</ArticleId><ArticleId IdType="pubmed">17895242</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouret S.G. Neurodevelopmental actions of leptin. Brain Res. 2010;1350:2&#x2013;9. doi: 10.1016/j.brainres.2010.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.04.011</ArticleId><ArticleId IdType="pmc">PMC3654158</ArticleId><ArticleId IdType="pubmed">20399755</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y., Yamashita T. The Effects of Leptin on Glial Cells in Neurological Diseases. Front. Neurosci. 2019;13:828. doi: 10.3389/fnins.2019.00828.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00828</ArticleId><ArticleId IdType="pmc">PMC6692660</ArticleId><ArticleId IdType="pubmed">31447640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.M., Phan K., Highton-Williamson E., Strikwerda-Brown C., Caga J., Ramsey E., Zoing M., Devenney E., Kim W.S., Hodges J.R., et al. Eating peptides: Biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Ann. Clin. Transl. Neurol. 2019;6:486&#x2013;495. doi: 10.1002/acn3.721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.721</ArticleId><ArticleId IdType="pmc">PMC6414477</ArticleId><ArticleId IdType="pubmed">30911572</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C., Baiocchi C., Bongioanni P., Cova E., Guareschi S., Metelli M.R., Rossi B., Sbalsi I., Cuccia M.C., Ceroni M. TNF and sTNFR1/2 plasma levels in ALS patients. J. Neuroimmunol. 2008;194:123&#x2013;131. doi: 10.1016/j.jneuroim.2007.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.028</ArticleId><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronin E., Pouchy C., Khosravi M., Hilaire M., Gr&#xe9;goire S., Casrouge A., Kassem S., Sleurs D., Martin G.H., Chanson N., et al. Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells. Proc. Natl. Acad. Sci. USA. 2021;118:e2014043118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020675</ArticleId><ArticleId IdType="pubmed">33766913</ArticleId></ArticleIdList></Reference><Reference><Citation>Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2&#x2013;22. doi: 10.1016/j.neuroscience.2015.06.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.06.038</ArticleId><ArticleId IdType="pubmed">26117714</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R., Pezzini F., Pucci M., Rossi S., Facchiano F., Marastoni D., Montagnana M., Lippi G., Reynolds R., Calabrese M. Changes in Cerebrospinal Fluid Balance of TNF and TNF Receptors in Na&#xef;ve Multiple Sclerosis Patients: Early Involvement in Compartmentalised Intrathecal Inflammation. Cells. 2021;10:1712. doi: 10.3390/cells10071712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071712</ArticleId><ArticleId IdType="pmc">PMC8303813</ArticleId><ArticleId IdType="pubmed">34359880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson M.M., Johannes R., Liu C., Huan T., Yao C., Miao X., Murabito J.M., Dupuis J., Levy D., Benjamin E.J., et al. Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study. Front. Pharmacol. 2018;9:207. doi: 10.3389/fphar.2018.00207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00207</ArticleId><ArticleId IdType="pmc">PMC5928448</ArticleId><ArticleId IdType="pubmed">29740313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shai I., Schulze M.B., Manson J.E., Rexrode K.M., Stampfer M.J., Mantzoros C., Hu F.B. A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care. 2005;28:1376&#x2013;1382. doi: 10.2337/diacare.28.6.1376.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.28.6.1376</ArticleId><ArticleId IdType="pubmed">15920055</ArticleId></ArticleIdList></Reference><Reference><Citation>Medler J., Wajant H. Tumor necrosis factor receptor-2 (TNFR2): An overview of an emerging drug target. Expert Opin. Ther. Targets. 2019;23:295&#x2013;307. doi: 10.1080/14728222.2019.1586886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2019.1586886</ArticleId><ArticleId IdType="pubmed">30856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M.A., Selak M.A., Xiang Z., Krainc D., Neve R.L., Kraemer B.C., Watts J.L., Kalb R.G. Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J. Neurosci. 2012;32:1123&#x2013;1141. doi: 10.1523/JNEUROSCI.6554-10.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6554-10.2012</ArticleId><ArticleId IdType="pmc">PMC3742882</ArticleId><ArticleId IdType="pubmed">22262909</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera N.D., Turner B.J. AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis. Neurochem. Res. 2016;41:544&#x2013;553. doi: 10.1007/s11064-015-1665-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-015-1665-3</ArticleId><ArticleId IdType="pubmed">26202426</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.J., Lee L.M., Lai H.L., Chern Y. Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett. 2015;589:432&#x2013;439. doi: 10.1016/j.febslet.2014.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.12.029</ArticleId><ArticleId IdType="pubmed">25592834</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera N.D., Sheean R.K., Scott J.W., Kemp B.E., Horne M.K., Turner B.J. Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS ONE. 2014;9:e90449. doi: 10.1371/journal.pone.0090449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090449</ArticleId><ArticleId IdType="pmc">PMC3942426</ArticleId><ArticleId IdType="pubmed">24595038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb H.M., Sharp P.S., Rahmani-Kondori N., Wells D.J. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1 G93A mouse model of ALS and is harmful in female mice. PLoS ONE. 2011;6:e24189. doi: 10.1371/journal.pone.0024189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024189</ArticleId><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun Y.C., Jeong S.G., Kim S.H., Cho G.W. Reduced sirtuin 1/adenosine monophosphate-activated protein kinase in amyotrophic lateral sclerosis patient-derived mesenchymal stem cells can be restored by resveratrol. J. Tissue Eng. Regen. Med. 2019;13:110&#x2013;115. doi: 10.1002/term.2776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/term.2776</ArticleId><ArticleId IdType="pubmed">30479062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Perera L.M., H&#xf6;ving A.L., Schmidt K.E., Cenan S., Wohllebe M., Greiner J.F.W., Kaltschmidt C., Simon M., Knabbe C., Kaltschmidt B. Neuroprotection Mediated by Human Blood Plasma in Mouse Hippocampal Slice Cultures and in Oxidatively Stressed Human Neurons. Int. J. Mol. Sci. 2021;22:9567. doi: 10.3390/ijms22179567.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179567</ArticleId><ArticleId IdType="pmc">PMC8430756</ArticleId><ArticleId IdType="pubmed">34502475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Li X., Li X., Yang W., Yu S. Blood Plasma of Patients with Parkinson&#x2019;s Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity. Park. Dis. 2016;2016:7596482. doi: 10.1155/2016/7596482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/7596482</ArticleId><ArticleId IdType="pmc">PMC5124690</ArticleId><ArticleId IdType="pubmed">27965913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubai T., Noda Y., Ito K., Nakao M., Seino Y., Oiso Y., Hamada Y. Insulin elevates leptin secretion and mRNA levels via cyclic AMP in 3T3-L1 adipocytes deprived of glucose. Heliyon. 2016;2:e00194. doi: 10.1016/j.heliyon.2016.e00194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2016.e00194</ArticleId><ArticleId IdType="pmc">PMC5121139</ArticleId><ArticleId IdType="pubmed">27896318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>